home / stock / mrus / mrus news

MRUS News and Press, Merus N.V. From 10/25/19

Stock Information
Company Name: Merus N.V.
Stock Symbol: MRUS
Market: NASDAQ
Website: merus.nl
Menu
MRUS MRUS Quote MRUS Short MRUS News MRUS Articles MRUS Message Board
Get MRUS Alerts

News, Short Squeeze, Breakout and More Instantly...
MRUS - Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

UTRECHT, The Netherlands and BOSTON, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage bispecific antibody company developing Biclonics®, innovative full-length h...
MRUS - Merus reports Q2 results

Merus (NASDAQ: MRUS ): Q2 GAAP EPS of -€0.51. More news on: Merus N.V., Earnings news and commentary, Healthcare stocks news, Read more ...

MRUS - Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update

UTRECHT, The Netherlands, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific...

MRUS - Kicking The Tires On Merus

Capitalism tries for a delicate balance: It attempts to work things out so that everyone gets just enough stuff to keep them from getting violent and trying to take other people's stuff. " - George Carlin Today, we take a look at a small developmental firm focused on immunotherapy. The co...
MRUS - Merus (MRUS) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow

The following slide deck was published by Merus N.V. in conjunction with this Read more ...

MRUS - Merus to Present at the Jefferies 2019 Healthcare Conference

UTRECHT, Netherlands, June 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibo...

MRUS - Merus reports Q1 results

Merus (NASDAQ: MRUS ): Q1 GAAP EPS of -€0.26. More news on: Merus N.V., Earnings news and commentary, Healthcare stocks news, Read more ...

MRUS - Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update

UTRECHT, The Netherlands, May 30, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific ant...

MRUS - Merus Announces 2019 Annual General Meeting of Shareholders

UTRECHT, The Netherlands, May 23, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific ant...

MRUS - Merus to Present at the RBC Capital Markets 2019 Healthcare Conference

UTRECHT, Netherlands, May 20, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibod...
Previous 10 Next 10